CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the effect of this information on current and future clinical practice.
  • Appreciate recently presented Phase III trial findings supporting the efficacy of adjuvant osimertinib for patients with NSCLC with EGFR mutations after complete resection, and consider the potential effect of this information on current and future clinical practice.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC to personalize therapeutic recommendations.
  • Assess available research evidence with approved and emerging RET inhibitors, and use this information to guide clinical care and protocol decisions for patients with newly diagnosed or progressive NSCLC harboring a RET fusion.
  • Evaluate available clinical trial findings supporting the role of approved and investigational MET inhibitors, and identify patients with MET exon 14 skipping mutations who might benefit from treatment with these novel compounds.
  • Recall the biologic rationale for and available data with the use of commercially available HER2-directed therapies for patients with NSCLC with HER2 overexpression or mutation, and discern the current and potential clinical applicability of this strategy.
  • Discuss the clinical relevance of a positive ROS1 mutation test result with appropriate patients with NSCLC, and optimally sequence available therapies for those with these genetic abnormalities.
  • Recall the design of ongoing clinical trials evaluating other novel targeted strategies in patients with NSCLC and various genomic alterations, and counsel appropriate individuals about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Alexander E Drilon, MD
  Chief, Early Drug Development Service
  Associate Attending Physician
  Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, ArcherDX Inc, AstraZeneca Pharmaceuticals LP, Axis Pharmaceutics, Bayer HealthCare Pharmaceuticals, BeiGene, BerGenBio ASA, Blueprint Medicines, Elevation Oncology, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Ignyta Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MORE Health Inc, Pfizer Inc, Remedica Ltd, Takeda Oncology, TP Therapeutics Inc, Tyra Biosciences, Verastem Inc, WebMD; Contracted Research: Exelixis Inc, Foundation Medicine, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Food and Beverage: Merck, Puma Biotechnology Inc; Royalties: Wolters Kluwer; Other: Boehringer Ingelheim Pharmaceuticals Inc, Merus BV.
  
  Professor Solange Peters, MD, PhD
  Head, Medical Oncology
  Chair, Thoracic Malignancies
  Oncology Department
  Lausanne University Hospital (CHUV)
  Lausanne, Switzerland
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, BioInvent International AB, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm Group, F Hoffmann-La Roche Ltd, Foundation Medicine, Illumina Inc, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Takeda Oncology; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Illumina Inc, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: Academic trials.
  
  Suresh S Ramalingam, MD
  Professor of Hematology and Medical Oncology
  Roberto C Goizueta Chair for Cancer Research
  Director, Division of Medical Oncology
  Deputy Director, Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, A GSK Company.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by education grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Lilly and Merck.
  
  Release date: October 2020
  Expiration date: October 2021